Rapport Therapeutics, Inc. (RAPP) Form 424B5 — Oct 27, 2026
Rapport Therapeutics (Nasdaq: RAPP) filed a preliminary prospectus supplement for an offering of Convertible Senior Notes due December 1, 2032, with Morgan Stanley, Leerink Partners, and Evercore ISI as underwriters. Pricing, principal amount, coupon, and conversion price are left blank pending completion of the deal. The convertible notes offering runs concurrently with a separate equity offering and an unregistered private placement, with proceeds intended primarily to fund ongoing and planned clinical trials for RAP-219 plus general corporate purposes.
Key figures
- Cash Position
- 436077000
- Shares Outstanding
- 47955079
- Last Reported Sale Price
- 25.33
- Total Stockholders Equity
- 422926000
- Maturity Date
- December 1, 2032
- Last Sale Price Date
- October 26, 2026
- Placement Agent Fee
- 6% of total purchase price of private placement shares
- Options Outstanding
- 8030456
- Interest Payment Dates
- June 1 and December 1, beginning June 1, 2027
- First Redemption Eligibility
- December 6, 2030
- Weighted Avg Option Exercise Price
- 16.43
- Partial Redemption Minimum Outstanding
- $75.0 million aggregate principal
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.